Cargando…

Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag

The occurrence of chronic myeloid leukemia (CML), or other myeloproliferative diseases, after the development of idiopathic thrombocytopenic purpura (ITP) is very rare in the current medical literature. Considering the advances in ITP management, and the wide use of new drugs for ITP and CML, we rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Autore, Francesco, Sora’, Federica, Chiusolo, Patrizia, Minnella, Gessica, Colangelo, Maria, Rossi, Elena, Sica, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708281/
https://www.ncbi.nlm.nih.gov/pubmed/34946271
http://dx.doi.org/10.3390/medicina57121326
_version_ 1784622644959641600
author Autore, Francesco
Sora’, Federica
Chiusolo, Patrizia
Minnella, Gessica
Colangelo, Maria
Rossi, Elena
Sica, Simona
author_facet Autore, Francesco
Sora’, Federica
Chiusolo, Patrizia
Minnella, Gessica
Colangelo, Maria
Rossi, Elena
Sica, Simona
author_sort Autore, Francesco
collection PubMed
description The occurrence of chronic myeloid leukemia (CML), or other myeloproliferative diseases, after the development of idiopathic thrombocytopenic purpura (ITP) is very rare in the current medical literature. Considering the advances in ITP management, and the wide use of new drugs for ITP and CML, we report an unusual case with this association. Our case report focused on a 64-year-old man with long-standing ITP treated with eltrombopag, who developed hyperleukocytosis during follow-up; after specific laboratory exams, it was diagnosed as CML and he began treatment with imatinib. The treatment with eltrombopag was balanced with imatinib to stabilize his platelet count. Data on bcr-abl and JAK2 transcripts were collected and revealed an optimal response with the achievement of negativization of both molecular signatures. We could demonstrate that treatment with imatinib and eltrombopag was well tolerated and allowed complete molecular remission of CML to be achieved, as well as of ITP.
format Online
Article
Text
id pubmed-8708281
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87082812021-12-25 Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag Autore, Francesco Sora’, Federica Chiusolo, Patrizia Minnella, Gessica Colangelo, Maria Rossi, Elena Sica, Simona Medicina (Kaunas) Case Report The occurrence of chronic myeloid leukemia (CML), or other myeloproliferative diseases, after the development of idiopathic thrombocytopenic purpura (ITP) is very rare in the current medical literature. Considering the advances in ITP management, and the wide use of new drugs for ITP and CML, we report an unusual case with this association. Our case report focused on a 64-year-old man with long-standing ITP treated with eltrombopag, who developed hyperleukocytosis during follow-up; after specific laboratory exams, it was diagnosed as CML and he began treatment with imatinib. The treatment with eltrombopag was balanced with imatinib to stabilize his platelet count. Data on bcr-abl and JAK2 transcripts were collected and revealed an optimal response with the achievement of negativization of both molecular signatures. We could demonstrate that treatment with imatinib and eltrombopag was well tolerated and allowed complete molecular remission of CML to be achieved, as well as of ITP. MDPI 2021-12-03 /pmc/articles/PMC8708281/ /pubmed/34946271 http://dx.doi.org/10.3390/medicina57121326 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Autore, Francesco
Sora’, Federica
Chiusolo, Patrizia
Minnella, Gessica
Colangelo, Maria
Rossi, Elena
Sica, Simona
Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
title Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
title_full Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
title_fullStr Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
title_full_unstemmed Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
title_short Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
title_sort chronic myeloid leukemia in a patient with previous idiopathic thrombocytopenic purpura: how to manage imatinib together with eltrombopag
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708281/
https://www.ncbi.nlm.nih.gov/pubmed/34946271
http://dx.doi.org/10.3390/medicina57121326
work_keys_str_mv AT autorefrancesco chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag
AT sorafederica chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag
AT chiusolopatrizia chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag
AT minnellagessica chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag
AT colangelomaria chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag
AT rossielena chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag
AT sicasimona chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag